Literature DB >> 32847936

Characteristics and Outcomes for Secondary Breast Cancer in Childhood, Adolescent, and Young Adult Cancer Survivors Treated with Radiation.

Candice A M Sauder1,2, Qian Li3, Alisha Othieno4, Daisy Cruz4, Mili Arora2,5, Richard J Bold4,2, Fredrick J Meyers2,5, Theresa H M Keegan3,5.   

Abstract

BACKGROUND: Radiotherapy is used to treat many adolescent and young adult (AYA) and childhood cancer patients and is a risk factor for secondary breast cancer. While premenopausal breast cancer is inherently more aggressive, no studies to date have evaluated the characteristics and breast cancer-specific survival (BCSS) of premenopausal secondary breast cancer after radiotherapy in AYA and childhood cancer survivors.
METHODS: Female patients ages 12 to 50 diagnosed with primary breast cancer from 1988 to 2014 (n = 107,751) were obtained from the California Cancer Registry and compared with similar aged patients with secondary breast cancer who were treated with radiotherapy for their primary tumor (n = 1,147) from ages 12 to 39. We examined BCSS using multivariable Cox proportional hazards regression.
RESULTS: The secondary breast cancer cohort was more likely to be Hispanic or Black, be 35 to 45 years of age, have earlier stage tumors, be higher grade, have no lymph node involvement, and be hormone receptor negative. All women showed worse BCSS for large tumor size, lymph node involvement, and hormone receptor-negative status. BCSS was worse for women with secondary breast cancer both overall (hazard ratio, 1.98; 95% confidence interval, 1.77-2.23) and in all subgroups considered. Associations were most pronounced in Hispanics, Asian/Pacific Islanders, and younger women, as well as those with earlier stage, lymph node-negative, and hormone receptor-positive disease.
CONCLUSIONS: BCSS is significantly decreased among all survivors of childhood and AYA cancer treated with radiotherapy that develop a secondary breast cancer, including women with good prognostic features. IMPACT: Therefore, we may need to consider alternative and even more aggressive treatment in what were considered low-risk populations previously. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2020        PMID: 32847936      PMCID: PMC9377811          DOI: 10.1158/1055-9965.EPI-20-0260

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.090


  39 in total

1.  Mortality After Breast Cancer Among Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.

Authors:  Chaya S Moskowitz; Joanne F Chou; Joseph P Neglia; Ann H Partridge; Rebecca M Howell; Lisa R Diller; Danielle Novetsky Friedman; Dana Barnea; Lindsay M Morton; Lucie M Turcotte; Michael A Arnold; Wendy M Leisenring; Gregory T Armstrong; Leslie L Robison; Kevin C Oeffinger; Tara O Henderson
Journal:  J Clin Oncol       Date:  2019-07-01       Impact factor: 44.544

2.  Survival differences in breast cancer among racial/ethnic groups: a population-based study.

Authors:  A Boyer-Chammard; T H Taylor; H Anton-Culver
Journal:  Cancer Detect Prev       Date:  1999

3.  Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry.

Authors:  Katrina R Bauer; Monica Brown; Rosemary D Cress; Carol A Parise; Vincent Caggiano
Journal:  Cancer       Date:  2007-05-01       Impact factor: 6.860

4.  Young age as an independent adverse prognostic factor in premenopausal patients with breast cancer.

Authors:  Peter C Dubsky; Michael F X Gnant; Susanne Taucher; Sebastian Roka; Daniela Kandioler; Barbara Pichler-Gebhard; Irene Agstner; Michael Seifert; Paul Sevelda; Raimund Jakesz
Journal:  Clin Breast Cancer       Date:  2002-04       Impact factor: 3.225

5.  Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease.

Authors:  Jennifer L Gnerlich; Anjali D Deshpande; Donna B Jeffe; Allison Sweet; Nick White; Julie A Margenthaler
Journal:  J Am Coll Surg       Date:  2009-01-21       Impact factor: 6.113

6.  Natural history of node-negative breast cancer: are conventional prognostic factors predictors of time to relapse?

Authors:  Michel Héry; Thierry Delozier; Alain Ramaioli; Jean-Pierre Julien; Brigitte de Lafontan; Thierry Petit; Catherine de Ghislain; Béatrice Weber; Jacques Bonneterre; Eric Teissier
Journal:  Breast       Date:  2002-10       Impact factor: 4.380

7.  Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update.

Authors:  B Fisher; M Bauer; D L Wickerham; C K Redmond; E R Fisher; A B Cruz; R Foster; B Gardner; H Lerner; R Margolese
Journal:  Cancer       Date:  1983-11-01       Impact factor: 6.860

8.  Dose to the contralateral breast from radiotherapy and risk of second primary breast cancer in the WECARE study.

Authors:  Marilyn Stovall; Susan A Smith; Bryan M Langholz; John D Boice; Roy E Shore; Michael Andersson; Thomas A Buchholz; Marinela Capanu; Leslie Bernstein; Charles F Lynch; Kathleen E Malone; Hoda Anton-Culver; Robert W Haile; Barry S Rosenstein; Anne S Reiner; Duncan C Thomas; Jonine L Bernstein
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-06-14       Impact factor: 7.038

9.  Second Primary Malignant Neoplasms and Survival in Adolescent and Young Adult Cancer Survivors.

Authors:  Theresa H M Keegan; Archie Bleyer; Aaron S Rosenberg; Qian Li; Melanie Goldfarb
Journal:  JAMA Oncol       Date:  2017-11-01       Impact factor: 31.777

Review 10.  Life-course origins of the ages at menarche and menopause.

Authors:  Michele R Forman; Lauren D Mangini; Rosenie Thelus-Jean; Mark D Hayward
Journal:  Adolesc Health Med Ther       Date:  2013-01-18
View more
  1 in total

1.  Subsequent Primary Cancer Risk Among 5-Year Survivors of Adolescent and Young Adult Cancers.

Authors:  Hyuna Sung; Rebecca L Siegel; Noorie Hyun; Kimberly D Miller; K Robin Yabroff; Ahmedin Jemal
Journal:  J Natl Cancer Inst       Date:  2022-08-08       Impact factor: 11.816

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.